Healthy
Conditions
Brief summary
To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BIRT 2584 XX in single rising oral doses of 5 mg to 700 mg in a polyethylene glycol 400 (PEG 400) solution in healthy subjects
Interventions
DRUGBIRT 2584 XX
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
MALE
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>=18 and \<=50 years * BMI \>=18.5 and \<=29.9 kg/m2
Exclusion criteria
* Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, haematological, oncological or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * Relevant history of orthostatic hypotension, fainting spells or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (\> 24 hours) (\< 1 month prior to administration or during the trial) * Use of any drugs, which might influence the results of the trial, (\< 10 days prior to study drug administration or expected during the trial) * Participation in another trial with an investigational drug (\< 2 months prior to administration or expected during trial) * Smoker (\> 10 cigarettes or \>3 cigars or \>3 pipes/day) * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood donation or loss \> 400 mL, \< 1 month prior to administration or expected during the trial * Clinically relevant laboratory abnormalities * Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval \> 110 ms or QT interval, Bazett correction (QTcB) \> 450 ms or QT interval \>500 ms * Inability to comply with dietary regimen of study centre * Inability to comply with investigator's instructions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | Up to 16 days after drug administration |
| Number of participants with clinically significant changes in vital signs | Up to 16 days after drug administration |
| Number of participants with abnormal changes in clinical laboratory parameters | Up to 16 days after drug administration |
| Number of participants with abnormal findings in 12-lead ECG (electrocardiogram) | Up to 16 days after drug administration |
| Number of participants with abnormal findings in physical examination | Screening and up to 16 days after drug administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| t1/2 (terminal half-life of the analyte in plasma) | Up to 360 hours after drug administration | — |
| MRT(mean residence time of the analyte in the body) | Up to 360 hours after drug administration | — |
| CL/F (apparent oral clearance in plasma after oral administration) | Up to 360 hours after drug administration | — |
| Vz/F (apparent volume of distribution during the terminal phase λz) dose) | Up to 360 hours after drug administration | — |
| Cmax (maximum concentration in plasma) | Up to 360 hours after drug administration | — |
| fe0-48 (fraction of analyte eliminated in urine from 0-48 hours) | Up to 48 hours after drug administration | — |
| CLR,0-48 (renal clearance of the analyte from 0-48 hours) | Up to 48 hours after drug administration | — |
| Receptor occupancy as determined by binding of anti-LFA-1 antibody fragment (Fab) | Up to 360 hours after drug administration | — |
| Inhibition of IL-2 production | Up to 360 hours after drug administration | in response to superantigen challenge ex vivo |
| Ae0-48 (amount of analyte that is eliminated in urine from 0-48 hours) | Up to 48 hours after drug administration | — |
| tmax (time from dosing to maximum concentration) | Up to 360 hours after drug administration | — |
| AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time) interval from 0 extrapolated to infinity) | Up to 360 hours after drug administration | — |
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time) interval from 0 to the last quantifiable analyte plasma concentration) | Up to 360 hours after drug administration | — |
| λz (terminal rate constant in plasma) | Up to 360 hours after drug administration | — |
Outcome results
None listed